SETTING: Multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid and rifampicin) has emerged as a serious global public health problem, especially in the former Soviet republics. The extent of the problem in Georgia has been incompletely defined. OBJECTIVE: To determine the prevalence and risk factors for MDR-TB in Georgia. DESIGN: A population-based study was carried out between July 2005 and May 2006. RESULTS: Of 1314 patients with acid-fast bacilli smear- and culture-positive pulmonary tuberculosis (TB), 799 (60.8%) were newly diagnosed patients and 515 (39.2%) had been treated previously. Overall, 733 (56%) patients had resistance to at least one anti-tuberculosis drug and 195 (15%) had MDR-TB. Patients who had been treated previously for TB were significantly more likely to have MDR-TB than newly diagnosed patients (141/515 [27.4%] vs. 54/794 [6.8%], OR 5.27, 95%CI 3.75-7.41). In multivariate analysis, previous TB treatment (aOR 5.47, 95%CI 3.87-7.74) and female sex (aOR1.58, 95%CI 1.02-2.32) were independent risk factors for the presence of MDR-TB. CONCLUSIONS: Drug-resistant TB, including MDR-TB, has emerged as a major public health problem in Georgia. Further TB control efforts need to be implemented to prevent the development of new cases of MDR-TB and to treat existing patients with MDR-TB.
SETTING: Multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid and rifampicin) has emerged as a serious global public health problem, especially in the former Soviet republics. The extent of the problem in Georgia has been incompletely defined. OBJECTIVE: To determine the prevalence and risk factors for MDR-TB in Georgia. DESIGN: A population-based study was carried out between July 2005 and May 2006. RESULTS: Of 1314 patients with acid-fast bacilli smear- and culture-positive pulmonary tuberculosis (TB), 799 (60.8%) were newly diagnosed patients and 515 (39.2%) had been treated previously. Overall, 733 (56%) patients had resistance to at least one anti-tuberculosis drug and 195 (15%) had MDR-TB. Patients who had been treated previously for TB were significantly more likely to have MDR-TB than newly diagnosed patients (141/515 [27.4%] vs. 54/794 [6.8%], OR 5.27, 95%CI 3.75-7.41). In multivariate analysis, previous TB treatment (aOR 5.47, 95%CI 3.87-7.74) and female sex (aOR1.58, 95%CI 1.02-2.32) were independent risk factors for the presence of MDR-TB. CONCLUSIONS: Drug-resistant TB, including MDR-TB, has emerged as a major public health problem in Georgia. Further TB control efforts need to be implemented to prevent the development of new cases of MDR-TB and to treat existing patients with MDR-TB.
Authors: D M Weinstock; O Hahn; M Wittkamp; K A Sepkowitz; G Khechinashvili; H M Blumberg Journal: Int J Tuberc Lung Dis Date: 2001-02 Impact factor: 2.373
Authors: R Zalesky; F Abdullajev; G Khechinashvili; M Safarian; T Madaras; M Grzemska; E Englund; S Dittmann; M Raviglione Journal: Int J Tuberc Lung Dis Date: 1999-05 Impact factor: 2.373
Authors: A Aerts; M Habouzit; L Mschiladze; N Malakmadze; N Sadradze; O Menteshashvili; F Portaels; P Sudre Journal: Int J Tuberc Lung Dis Date: 2000-12 Impact factor: 2.373
Authors: M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione Journal: JAMA Date: 2000-05-17 Impact factor: 56.272
Authors: D C Richards; T Mikiashvili; J J Parris; E V Kourbatova; J C E Wilson; N Shubladze; T Tsertvadze; G Khechinashvili; C del Rio; H M Blumberg Journal: Int J Tuberc Lung Dis Date: 2006-04 Impact factor: 2.373
Authors: M A Espinal; K Laserson; M Camacho; Z Fusheng; S J Kim; R E Tlali; I Smith; P Suarez; M L Antunes; A G George; N Martin-Casabona; P Simelane; K Weyer; N Binkin; M C Raviglione Journal: Int J Tuberc Lung Dis Date: 2001-10 Impact factor: 2.373
Authors: A Pablos-Méndez; M C Raviglione; A Laszlo; N Binkin; H L Rieder; F Bustreo; D L Cohn; C S Lambregts-van Weezenbeek; S J Kim; P Chaulet; P Nunn Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: Nirali S Desai; Nestani Tukvadze; Jennifer K Frediani; Maia Kipiani; Ekaterine Sanikidze; Memorie M Nichols; Gautam Hebbar; Russell R Kempker; Veriko Mirtskhulava; Iagor Kalandadze; Shabnam Seydafkan; Nilay Sutaria; Tai C Chen; Henry M Blumberg; Thomas R Ziegler; Vin Tangpricha Journal: Nutrition Date: 2012-02-02 Impact factor: 4.008
Authors: Russell R Kempker; Nestani Tukvadze; Lisa Sthreshley; Lisa Sharling; Dawn L Comeau; Matthew J Magee; Carlos Del Rio; Zaza Avaliani; Henry M Blumberg Journal: Am J Trop Med Hyg Date: 2018-02-01 Impact factor: 2.345
Authors: Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler Journal: JCI Insight Date: 2020-05-21
Authors: Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg Journal: Int J Infect Dis Date: 2012-03-17 Impact factor: 3.623
Authors: Nestan Tukvadze; Ekaterina Sanikidze; Maia Kipiani; Gautam Hebbar; Kirk A Easley; Neeta Shenvi; Russell R Kempker; Jennifer K Frediani; Veriko Mirtskhulava; Jessica A Alvarez; Nino Lomtadze; Lamara Vashakidze; Li Hao; Carlos Del Rio; Vin Tangpricha; Henry M Blumberg; Thomas R Ziegler Journal: Am J Clin Nutr Date: 2015-09-23 Impact factor: 7.045
Authors: Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen Journal: Lancet Date: 2014-03-24 Impact factor: 79.321
Authors: D Baliashvili; R R Kempker; H M Blumberg; G Kuchukhidze; T Merabishvili; A Aslanikashvili; M J Magee Journal: Public Health Action Date: 2018-09-21